Incyte Corporation (NASDAQ:INCY) insider Paul Trower sold 3,000 shares of the stock in a transaction on Friday, August 4th. The shares were sold at an average price of $125.25, for a total value of $375,750.00. Following the sale, the insider now owns 11,853 shares in the company, valued at approximately $1,484,588.25. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Paul Trower also recently made the following trade(s):
- On Wednesday, July 5th, Paul Trower sold 3,000 shares of Incyte Corporation stock. The stock was sold at an average price of $126.18, for a total value of $378,540.00.
- On Monday, June 5th, Paul Trower sold 3,000 shares of Incyte Corporation stock. The stock was sold at an average price of $132.50, for a total value of $397,500.00.
Shares of Incyte Corporation (NASDAQ:INCY) traded down 0.45% on Friday, reaching $121.19. The company had a trading volume of 958,477 shares. The company’s 50-day moving average price is $129.70 and its 200 day moving average price is $129.55. Incyte Corporation has a 52 week low of $77.58 and a 52 week high of $153.15. The firm’s market capitalization is $24.93 billion.
Incyte Corporation (NASDAQ:INCY) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.01. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The company had revenue of $326.40 million during the quarter, compared to analyst estimates of $318.45 million. During the same quarter in the previous year, the firm earned $0.18 earnings per share. The business’s revenue was up 32.5% on a year-over-year basis. On average, analysts expect that Incyte Corporation will post ($0.86) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was published by BNB Daily and is the sole property of of BNB Daily. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/incyte-corporation-nasdaqincy-insider-sells-375750-00-in-stock-updated.html.
INCY has been the topic of a number of recent research reports. Morgan Stanley reissued an “overweight” rating and set a $142.00 price target on shares of Incyte Corporation in a research report on Friday, May 19th. BMO Capital Markets increased their price target on Incyte Corporation from $144.00 to $146.00 and gave the stock an “outperform” rating in a research report on Friday, May 5th. Zacks Investment Research raised Incyte Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. BidaskClub raised Incyte Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, TheStreet downgraded Incyte Corporation from a “c+” rating to a “d+” rating in a research report on Thursday, May 4th. Eight analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. Incyte Corporation currently has an average rating of “Buy” and an average target price of $140.16.
Several institutional investors have recently modified their holdings of INCY. State Street Corp increased its position in shares of Incyte Corporation by 110.7% in the first quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock valued at $1,013,437,000 after buying an additional 3,983,207 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Incyte Corporation by 22.7% in the first quarter. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company’s stock valued at $2,060,638,000 after buying an additional 2,847,907 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Incyte Corporation by 4,570.1% in the second quarter. Janus Henderson Group PLC now owns 1,045,363 shares of the biopharmaceutical company’s stock valued at $131,622,000 after buying an additional 1,022,979 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of Incyte Corporation during the first quarter valued at about $85,751,000. Finally, Geode Capital Management LLC increased its position in shares of Incyte Corporation by 42.0% in the first quarter. Geode Capital Management LLC now owns 1,780,064 shares of the biopharmaceutical company’s stock valued at $237,618,000 after buying an additional 526,163 shares in the last quarter. Institutional investors and hedge funds own 91.54% of the company’s stock.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.